Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m2) in the treatment of advanced peritoneal metastatic disease: MINOS real-life multicenter study
Abstract
Introduction Oxaliplatin (Ox) is one of the recommended agents in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) that benefitted of several phase I trials. Based on these data, the dose of 120mg/m 2 was suggested by an expert consensus for fit patients with peritoneal metastases (PM) of gastrointestinal cancers. The aim of the current study is to determine the real-life feasibility and safety profile of this regimen. Material and methods This retrospective study included all patients treated with PIPAC-Ox 120mg/m 2 in six referral centers specialized in PM. The patients were assessed for all potential toxicities associated to high dose oxaliplatin. Adverse events were expressed with the use of CTCAE for medical complications and Clavien-Dindo for surgical complications. Logistic regression and multivariate analysis were performed. Results 259 PIPAC procedures were performed in 91 patients (53 male) diagnosed with unresectable PM of various origins; most patients (n=62) having colorectal PM. Concomitant IV 5FU was performed in 70 patients. All patients underwent the first PIPAC-Ox 120mg/m 2 , and 44 patients (48.3%) had ≥ 3 PIPAC. Abdominal pain was the most frequent grade III toxicity at the first PIPAC-Ox (n=34) while 30 patients routinely received continuous IV opioids. Nausea-vomiting and ascites infection were the others grade III toxicity observed at PIPAC 1, one in each case respectively. After PIPAC 3, RECIST partial/stable response in 68.2%; PRGS 1-2 in 77.3% and negative cytology in 50% of patients. Conclusions High-dose PIPAC-Ox is feasible and safe. Local and histological response are well identified. However abdominal pain remains a main concern and continuous IV protocols should be considered routinely.
Related
- Development and Psychometric Evaluation of the Peritoneal Dialysis Treatment Adherence Scale: A Multicenter Methodological Study.
- Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial
- Impact of Organ-Specific Severe Immune-Related Adverse Events on Long-Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5-Year Multicenter Multistate Analysis.
- Changes in Treatment Patterns and Survival Outcomes Across Therapeutic Eras in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study.
- Association of different traditional Chinese medicine treatment strategies with overall survival in patients with metastatic colorectal cancer: a multicenter real-world cohort study
BibTeX
@article{zambrano2026feasibility,
title = {{Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m2) in the treatment of advanced peritoneal metastatic disease: MINOS real-life multicenter study}},
author = {Diego Zambrano and Alexandru Lintis and Amaniel Kefleyesus and Abdelkader Taibi and Clarisse Eveno and Marc Pocard and Guillaume de Meeus and François Quénet and Vahan Kepenekian and Martin Hübner and Olivier Glehen and Olivia Sgarbura},
journal = {European Journal of Surgical Oncology},
year = {2026},
month = sep,
doi = {10.1016/j.ejso.2026.111731},
url = {https://hal.science/hal-05771087v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m2) in the treatment of advanced peritoneal metastatic disease: MINOS real-life multicenter study
AU - Diego Zambrano
AU - Alexandru Lintis
AU - Amaniel Kefleyesus
AU - Abdelkader Taibi
AU - Clarisse Eveno
AU - Marc Pocard
AU - Guillaume de Meeus
AU - François Quénet
AU - Vahan Kepenekian
AU - Martin Hübner
AU - Olivier Glehen
AU - Olivia Sgarbura
PY - 2026
DA - 2026/09/30
JO - European Journal of Surgical Oncology
DO - 10.1016/j.ejso.2026.111731
UR - https://hal.science/hal-05771087v1
AB - Introduction Oxaliplatin (Ox) is one of the recommended agents in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) that benefitted of several phase I trials. Based on these data, the dose of 120mg/m 2 was suggested by an expert consensus for fit patients with peritoneal metastases (PM) of gastrointestinal cancers. The aim of the current study is to determine the real-life feasibility and safety profile of this regimen. Material and methods This retrospective study included all patients treated with PIPAC-Ox 120mg/m 2 in six referral centers specialized in PM. The patients were assessed for all potential toxicities associated to high dose oxaliplatin. Adverse events were expressed with the use of CTCAE for medical complications and Clavien-Dindo for surgical complications. Logistic regression and multivariate analysis were performed. Results 259 PIPAC procedures were performed in 91 patients (53 male) diagnosed with unresectable PM of various origins; most patients (n=62) having colorectal PM. Concomitant IV 5FU was performed in 70 patients. All patients underwent the first PIPAC-Ox 120mg/m 2 , and 44 patients (48.3%) had ≥ 3 PIPAC. Abdominal pain was the most frequent grade III toxicity at the first PIPAC-Ox (n=34) while 30 patients routinely received continuous IV opioids. Nausea-vomiting and ascites infection were the others grade III toxicity observed at PIPAC 1, one in each case respectively. After PIPAC 3, RECIST partial/stable response in 68.2%; PRGS 1-2 in 77.3% and negative cytology in 50% of patients. Conclusions High-dose PIPAC-Ox is feasible and safe. Local and histological response are well identified. However abdominal pain remains a main concern and continuous IV protocols should be considered routinely.
SN - 0748-7983
SN - 1532-2157
ER -